

# WESTERN CAPE

Newsletter | Spring 2013

Letter from the Chairperson

Summary 1 | Cancer Update

Summary 2 | Omega 3 Update

Getting to know Catherine Day

Health Calendar 2013

Article | Nutrigenomics: Role of the Dietician

*The Omega-3 Edition*



# Welcome

## Letter from the Chairperson

Welcome to September! How the year has flown by... July saw the start of the new ADSA term and we had quite a significant change in our committee.

We said goodbye to Tracy Ugarchund, Maryke Gallegher (nee van Zyl), Deborah Hoepfl, Kelly Lynch and Leonore Ward. I enjoyed working with each and every one of you and would like to thank you for your support of ADSA WC over the last 2 years.

With goodbyes come hellos too! So I'd like to welcome onto the committee, Desiree du Preez (nee van Riet), Michelle Massyn, Janetta Harbron, Catherine Day and Bridget Hill. I look forward to a successful term together!

On the 13th of June we had our second event this year – we did a summary on cancer, and omega 3 update and had an interesting look at nutrigenomics. This newsletter gives you some information on these topics as well a review article on the interactions between dietary omega 3 fatty acids and genetic variants and the risk of disease. I hope you'll enjoy it!

I had the pleasure of attending the ADSA Exec meeting at the end of last month. Each branch has been given the task to come up with a fun and exciting tool for National Nutrition week – the topic is portion control this year. If you have any good ideas that we could use please mail them to me. The winning branch gets R1000, which we can then spend on our members!

I look forward to seeing you all soon!

Kind Regards

Kim

[kimh.rd@mweb.co.za](mailto:kimh.rd@mweb.co.za)

# Summary

## CANCER UPDATE

The report by Statistics SA on the Mortality and Causes of Death in South Africa, 2010 (April 2013):

- Cancer is ranked 6th among the main causes of death
- 5.9% in 2008
- 6.3% in 2009
- 6.7% in 2010

Early detection is the key to more successful outcomes of cancer. Consumer empowerment is critical to ensure that the right tests are done in time to reduce unnecessary suffering and enhance the chances of cure.

### Cancer in South African Women

- Breast cancer
- Cervical cancer
- Colorectal cancer
- Lung cancer
- Oesophageal cancer

### Cancer in South African Men

- Prostate cancer
- Lung cancer
- Oesophageal cancer
- Bladder cancer
- Colorectal cancer

A third of yearly cancer deaths are due to diet & physical activity habits (including overweight & obesity). Behaviours that can substantially reduce the lifetime risk of developing, or dying from, cancer:

- Avoiding exposure to tobacco products
- Maintaining a healthy weight
- Staying physically active throughout life
- Eating a healthy diet

American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention

1. Achieve and maintain a healthy weight throughout life
  - Be as lean as possible throughout life without being underweight

- Avoid excess weight gain at all ages
- For those who are currently overweight or obese, losing even a small amount of weight has health benefits and is a good place to start
- Engage in regular physical activity and limit consumption of high-calorie foods and beverages as key strategies for maintaining a healthy weight

#### 2. Consume a healthy diet, with an emphasis on plant foods

- Choose foods and beverages in amounts that help achieve and maintain a healthy weight
- Limit consumption of processed meat & red meat
- Eat at least 2.5 cups of vegetables and fruits each day
- Choose whole grains instead of refined grain products

#### 3. If you drink alcoholic beverages, limit consumption

- Drink no more than 1 drink per day for women or 2 per day for men

#### 4. Adopt a physically active lifestyle

- Adults should engage in at least 150 minutes of moderate intensity or 75 minutes of vigorous intensity activity each week, or an equivalent combination, preferably spread throughout the week
- Children and adolescents should engage in at least 1 hour of moderate or vigorous intensity activity each day, with vigorous intensity activity occurring at least 3 days each week
- Limit sedentary behaviour such as sitting, lying down, watching television, or other forms of screen-based entertainment
- Doing some physical activity above usual activities, no matter what one's level of activity, can have many health benefits

### Diet and Cancer

#### Dietary patterns and behaviours

- Individuals who eat less red and processed meat also tend to eat fewer refined grain products and consume more vegetables and fruits

# Summary

## How do they relate to cancer risk?

- Individuals who eat more processed and red meat, potatoes, refined grains, and sugar-sweetened beverages and foods are at a higher risk of developing certain cancers or dying from cancer
- Individuals who eat a diet that contains a variety of vegetables and fruits, whole grains, and fish or poultry or that is lower in red and processed meats is associated with a lower risk of developing certain cancers or dying from cancer

These studies provide consistent and compelling evidence that healthy dietary patterns are associated with a decreased risk of cancer, even though they do not, in and of themselves, indicate whether avoiding those foods associated with increased risk (e.g. red and processed meats) or eating foods related to lower risk (e.g. plant foods), or both, is most important

There have been attempts made to isolate specific nutrients from foods that have showed positive results, and study their effects as supplements, sometimes in very high doses

Many of these studies have however failed to confirm promising leads, and some have even shown harm

- No benefit has been shown for antioxidant supplements and cancer prevention
- Trials of beta-carotene for the prevention of lung cancer
- Selenium and Vitamin E Cancer Prevention Trial for the prevention of prostate cancer – failed to demonstrate any benefit and a more recent analysis of the trial data suggests that high-dose vitamin E supplements may actually promote a small increase in the risk
- Calcium lowered risk of colorectal cancer, but increased the risk of prostate cancer

**By: Kim Hofmann**



# Summary

## OMEGA 3 UPDATE

Triglycerides (fats and oils), phospholipids and sterols (cholesterol) are all defined as dietary fats. These dietary fats originate from either animals or plants.

The fatty acids found in these dietary fats are:

- Saturated fat
- Monounsaturated fat
- Polyunsaturated fat (omega-3 and 6)
- Trans fats

### The change in omega-6 vs. omega-3 ratio

During the past 150 years the typical omega-6 vs. omega-3 fatty acid ratio has been elevated dramatically from approximately 1:1 to 15-20:1. This increase is caused by significant changes in dietary habits and can have profound negative impacts on health.

### Metabolism of omega-3 and omega-6 fatty acids

The two metabolic pathways of omega-3 and omega-6 act independently of each other and have no crossover reactions. However, there is competition between these two series for their conversions, since both pathways use the same enzymes. In human diets LA is the main PUFA and intakes of ALA are generally low, which in turn leads to both cell and plasma levels of omega-6 derived from LA tending to be higher than the omega-3 levels.

### How does omega 3 work?

Omega-3 fatty acids appear to confer most benefits largely through DHA and EPA enrichment of membrane phospholipids. DHA and EPA in cellular membranes can release signalling molecules and alter the activity of membrane-bound proteins (receptors, ion channels etc). This will modify gene expression in the cell nucleus and subsequently result in cellular release of signalling molecules including certain eicosanoids.

Omega-3 plays an important role in the production of the powerful hormone-like substances called Prostaglandins. Prostaglandins help regulate many physiological functions such as blood pressure, nerve transmission, inflammatory and allergic responses, kidneys and gastrointestinal tract and production of other hormones.

Micronutrients such as iron, zinc, vitamin B6 and vitamin E are needed for the conversion of ALA and LA to EPA + DHA and AA through their role in elongation enzymes. Magnesium, zinc, Vitamins B3, B6 & C help increase the activity of your desaturase enzymes.

*Fresh tuna is considered to be a fatty fish, however, with canning the fat content of the tuna is substantially reduced - excluding canned tuna from the fatty fish group.*

# Summary

## Recommended intake of omega 3

For the adult population: 1-2 fatty fish meals per week or approximately 250mg of EPA plus DHA per day and 1750mg of EPA plus DHA per week. Most international groups and organizations recommend two servings of fatty fish per week, on average providing 450-500 mg EPA and DHA per day.

## Omega 3 and heart disease

There is convincing evidence that replacing SFA with PUFA decreases the risk of CHD.

## Omega 3 and hypertension

- Omega-3 intake is shown to be inversely related to blood pressure, albeit with small estimated effect size.
- Dietary omega-3 may contribute to both the prevention as well as the control of adverse blood pressure levels.

## Omega 3 and inflammation


- Inflammation is a normal part of the body's immediate reaction to infection or injury, but uncontrolled inflammation damages tissues.
- Uncontrolled inflammation plays a pivotal role in the pathology of diseases like rheumatoid arthritis, asthma and atherosclerosis.
- A recently identified lipid (fat) product our bodies make from EPA, called resolvins, helps explain how this omega-3 fat provides anti-inflammatory effects on our joints and improves blood flow.

## Omega 3 and cancer

- Meta-analysis indicated that fish consumption and possibly omega-3 intake inhibits colorectal carcinogenesis.
- Studies here showed a further reduction in risk in colorectal for each additional 100g of fish consumed in a week.

## Omega 3 and eye health

- In the Blue Mountains Eye Study population, a clear association was observed between a higher frequency of intake of fish (>1 per week) with decreased risk of late age age-related macular degeneration (AMD).
- The most significant change in the retinal phospholipids fatty acid composition after omega-3 intake is a large increase in the EPA/AA ratio in the retina.



### Omega 3 and brain health

- Fat makes up 50-60% of the brain and the nerves. DHA is the predominant structural fatty acid in the brain.
- DHA is particularly important in early life and may play a unique role in the structure of the eye and brain as an essential component of cell membrane.
- Recent studies also point to important roles for DHA in inhibition of oxidative stress-induced induction of pro-inflammatory genes and apoptosis in the brain and retina.
- EPA plays a more functional role, as its derivatives may affect blood flow, immune system function and hormonal balance, among others.
- Both EPA and DHA can affect numerous aspects of cell-signaling in the brain and nervous system, including gene expression.
- DHA derived NeuroprotectinD1 (NPD1) may benefit in the preservation of cognition, memory and healthy brain cell function.
- The content of DHA in the brain has been found to decrease with age with Alzheimer's Disease (AD).
- DHA supplementation (900 mg/day) has been shown to improve learning and memory in subjects with age-related cognitive decline.
- Observational studies suggest that higher DHA and/or fish intake reduce the risk of AD yet interventional studies suggest that supplemental DHA is not beneficial in AD.

### Omega 3 and depression

- Epidemiologic studies have suggested that consumption of fish oils may have some protective function against depression.
- Several studies with high-dose omega-3 have shown improvement in depression symptoms (especially in bipolar disorder). Large-scale, well-controlled trials are still needed to examine omega-3's clinical utility in depression.
- The observed effect of omega-3 may be caused by modulation of neurotransmitter metabolism and cell signal transduction.

*By: Megan Pentz-Kluyts*

*For the article on the interactions between dietary omega 3 fatty acids and genetic variants and risk of disease by Dolores Corella and Jose Ordova, [click here](#)*

# Getting to know

## Catherine Day

Family	It is just my husband and I – for now.
Place of birth	I am originally Eastern Cape born-and-bred. From a little town in the middle of no-where and between the mountains called Dordrecht.
High School	Queenstown Girls High School
Hobbies	Hiking, walking trails and reading
Pets	An adorable little black daschund – Mango
Favourite Holiday	Any holiday that includes the beach.
Destination	Budapest – Hungary! The most amazing city in Europe!
Favourite Food	Steak – true farm girl at heart.
Best Gift Ever	Love
Favourite T.V program	Suits
What are you doing when you are not working for ADSA?	Assistant lecturer at University of Cape Town and I practice privately in a part-time capacity from Tokai.
What do you like to do on an evening?	Taking the dog for a walk – followed by my version of trying to “Master-Chef-it-up! I love trying out new foods and dishes.
What do you fear the most?	Spiders and snakes!
What makes you laugh	The things my niece comes up with – it wasn’t me... it was the naughty crayons.
What is the first thing you do in the morning when you wake up?	Coffee (and a whole wheat rusk) – a must to start my day off on the right foot!
What annoys you the most?	Traffic
Best Quality	Organizational skills
Worst quality/habit?	Hiding things away from myself!
Last Book Read	50 Shades of Grey – wanted to see what all the fuss was about, over-rated!
Last 3 items purchased?	A marrow bone for Mango, yoghurt and receipt book
Personal Motto	Love food. Eat smart. Love life. AND You are your own worst enemy.. Because anything is possible – if you put your mind to it.



## HEALTH CALENDAR 2013

September  
2013



Sept	Oral Health Month "No Health without Oral Health"	PGWC: Oral Health 021-918 1611
Sept	Cervical and Breast Cancer Awareness Month	Cancer Association of South Africa 021-689 5347
Sept	Deaf Awareness Month "Hearing Awareness"	SA Association of Audiologists 012-667 4460
Sept	Muscular Dystrophy Awareness Month "Your support means hope"	Muscular Dystrophy Foundation 021-592 7306/084 557 1423
Sept	National Heart Awareness Month	Heart and Stroke Foundation SA 021-403 6450
Sept	National Month of Deaf People	Deaf Federation of SA 011-482 1610
Sept	World Alzheimer's Month "Raising Awareness of Alzheimer's disease"	Alzheimer's South Africa 021-979 2724/www.alzheimers.org.za
Sept	Female Sterilization Month	Association for Voluntary Sterilization 021-531 1665
Sept	School AIDS Month "AIDS Free Generation...Zero Infection, Zero Deaths, Zero Stigma in my life"	PGWC: HIV/AIDS, TB and STI 021-483 9933
1-7	Arbor Week	Environmental Affairs and Development Planning 021-483 2610
2-8	Pharmacy Week	PGWC: Pharmacy Services 021-483 5656
6	Casual Day	SA National Council for the Blind 012-452 3811
8	International Literacy Day	Centre for the Book 021-423 2669 Department of Social Development 021-483 4538
9	International Fetal Alcohol Spectrum Disorders Day (FASD) "Creating Awareness of danger of drinking alcohol during pregnancy"	SANCA 021-945 4080/1 FASIC 082 5099 530
9-15	National Physiotherapy Back Week	SA Society of Physiotherapy 011-615 3170
9-15	Kidney Awareness Week	National Kidney Foundation of SA 011-447 2531
10	World Suicide Prevention Day	The S.A Depression and Anxiety Group 011-262 6396
16	International Day for the Preservation of the Ozone Layer	
21	World Alzheimer's Day "Raising Awareness of Alzheimer's disease"	Alzheimer's South Africa 021-979 2724/ www.alzheimers.org.za Department of Social Development 021-483 3992
24	Heritage Day	Iziko Museum 021-481 3813
27	World Tourism Day	
29	World Heart Day	Heart and Stroke Foundation SA 021-403 6450
30 Sept -6 Oct	Week of Older Persons	Age-in-Action 021-426 4249

# October

## 2013

Oct	Mental Health Awareness Month "Youth and Depression"	Cape Mental Health 021-447 2416 SA Federation for Mental Health 011-781 1852
Oct	Cervical and Breast Cancer Awareness Month	Cancer Association of South Africa 021-689 5347
Oct	Social Development Month	Department of Social Development 021-483 4714
Oct	Eye Care Awareness Month	SA National Council for the Blind 012-452 3811
1	International Day of Older Persons	Age-in-Action 021-426 4249
4	World Animal Day	
4-10	International Animal Week	SPCA 021-700 4141
5	Habitat Day	Environmental Affairs and Development Planning 021-483 2610
6	Grandparents' Day	Age-in-Action 021-426 4249
7-11	Occupational Therapy Week	Occupational Therapy Association 012-362 5457
9-15	Nutrition Week	PGWC: Nutrition 021-483 2275
10	World Mental Health Day	The S.A Depression and Anxiety Group 011-262 6396
10	World Sight Day	SA National Council for the Blind 012-452 3811
10	International Older Persons Day	Department of Social Development 021-483 3992
10	International Day for Homeless People	Department of Social Development 021-483 8227/4115
12	International Arthritis Day	The Arthritis Foundation of SA 021-425 2344
12	World Hospice Palliative Care Day	Hospice Palliative Care Association 021-531 0277
15	International White Cane Safety Day	SA National Council for the Blind 012-452 3811
15	Global Handwashing Day	
16	World Food Day	PGWC: Nutrition 021-483 2275
17	International Day for the Eradication of Poverty	
17	Annual Infection Prevention and Control (IPC) Day	Provincial Infection Prevention & Control Committee (PIPCC) 021-938 5054
20	National Down Syndrome Day	Down Syndrome Association Western Cape 021-919 8533
20	World Osteoporosis Day "Capture the First Fracture"	National Osteoporosis Foundation of SA 021-931 7894 The Arthritis Foundation of SA 021-425 2344
29	World Stroke Day	Heart and Stroke Foundation SA 021-403 6450
29	World Psoriasis Day "Global access to treatment"	SA Psoriasis Association 021-404 5269 / 082 4069 725

# November

## 2013

Nov	Men's Health: Prostate and Testicular Cancer Awareness Month	Cancer Association of South Africa 021- 689 5347
Nov	Disability Month	Department of Social Development 021-483 4015
Nov	Men's Health Month	The ComaCare Trust 021 361 5434
1	National Children's Day	Department of Social Development 021-483 4153
4 -10	CPR Week	Heart and Stroke Foundation SA 021-403 6450
11-16	National Diabetes Week	
14	World Diabetes Day "Understand Diabetes and take control of your health"	Diabetes SA 021-425 4440 Heart and Stroke Foundation SA 021-403 6450
11-16	Obesity Week	Heart and Stroke Foundation SA 021-403 6450
19	International Men's Day	Department of Social Development 021-483 8227/4115 FAMSA 021-447 7951
19	World Day for the Prevention of Child Abuse and Neglect "Children's Rights/Child Protection"	RAPCAN 021 712 2330
20	World Chronic Obstructive Pulmonary Disease (COPD) Day	UCT Lung Institute 021-406 6901
21	World Fisheries Day	
23	Complementary Therapies Day	The Arthritis Foundation of SA 021-425 2344
25 Nov- 10 Dec	16 days of activism for no violence against women and children	Department of Social Development 021-483 8227/4115 PGWC: HIV/AIDS, TB and STI 021-483 3458 / 9933
27-29	National Kangaroo Mother Care Week "Bonding starts at Birth"	PGWC: Mowbray Maternity Hospital 021-659 5594

# December

## 2013

Dec	SunSmart: Skin Cancer Awareness Month	Cancer Association of SA (CANSA) 021-689 5347
1	World AIDS Day "AIDS Free Generation...Zero Infection, Zero Deaths, Zero Stigma in my life"	PGWC: HIV & AIDS, STI and TB 021-483 9938 FAMSA 021-447 7951 Iziko Museum 021-481 3813 Department of Social Development 021-483 4714
1	Emancipation Day	Iziko Museum 021-481 3813
3	National Transplant Day	Organ Donor Foundation 0800 226611 (toll free) Heart and Stroke Foundation SA 021-403 6450
3	International Day for Persons with Disabilities	WC Association for Persons with Disabilities 021-555 2881
5	Volunteer Day "Volunteering is healthy, it eradicates depression"	Volunteer Centre 021-674 5338
10	End of 16 Days of Activism	Department of Social Development 021-483 8227/4115
10	International Human Rights Day	

## Nutrigenomics Role of the Dietician

I have had the privilege to work with some of the most well known geneticist in the country and provide their clients a nutritional counselling service.

As this is still sometimes a controversial field in some circles, and also quite complicated at times, many dieticians may not have had much experience in counselling patients regarding their genetic profile.

To provide this service as a dietician it is important to keep up to date with the latest developments in the field of nutrigenomics and attend as many workshops as possible to get an idea how others are using it to the benefit of their patients and to see what new information has been discovered.

Dieticians play a major role in the counselling process as genetic risk factors has a nutritional aspect. Once a patient has decided to go for a genetic screening test, they may first be counselled by a genetic counsellor about the appropriate tests, if it will benefit them at all as well as the ethical considerations for the patient and their family.

There are currently a few options available. Patients may be screened for cardiovascular , cancer obesity , diabetes and even sports injury risks. These are all diseases of lifestyle and the genetic aspect is a small part of the puzzle. Once a genetic profile has been obtained, the dietician will receive a comprehensive report which gives you the following information: Genetic Mutations detected and their clinical significance. Relevant family history, patient medical history, pathology results (e.g. blood fats, glucose levels, CRP levels etc. ). As part of the team it is important to keep in contact with the patient's medical doctors, who will be involved in treatment (e.g. GP, oncologist, cardiologist etc.)



The results of the genetic tests provide focus and direction regarding some important aspects of the diet that one should focus on most. It is sometimes hard to implement changes and one can start with the ones that we know will definitely make a difference to the patient. These tests help eliminate a “shotgun” approach. It also motivates the patient to follow the diet more closely as they are faced with real risk as well as real treatment solutions to decrease the risk

For instance : I had a patient who recently was referred to me for weight loss.

She had a BMI of 43, and has been overweight all her life. She had recently developed diabetes and was on Insulin. She has a strong family history of Diabetes and breast cancer. (Siblings, parents , grandparents)


She had “tried everything” to lose weight. Her doctor wanted to perform genetic tests in order to possibly motivate her to the medical aid for bariatric surgery. (she was not very keen to do this)

The DNA test revealed at least 5 mutations which increased the risk for diabetes, overweight and obesity. Other risks included cancer risk . When I asked her if she thought the tests made a difference, she was very positive and said that she would highly recommend it . IT confirmed that she has a higher risk and that she had to work extra hard to overcome her problem She made concrete plans to start a good exercise programme (Something she had been putting off for a long time) .

She is making good progress and is on the road to long term permanent changes to her eating habits. She has already started losing some weight and is dealing with the psychological and social issues that has been associated with her weight problem all her life.

We are starting a peer group for dieticians who would like to learn more about this service. Case studies and journal articles will be discussed. For more information contact Annelie Smith at [annelie@anneliesmith.co.za](mailto:annelie@anneliesmith.co.za)

*By Annelie Smith (BSc Med Hon Clin Diet) RDSA*



# Contact Details

Chairperson of ADSA WC

**Kim Hofmann**

[kimh.rd@mweb.co.za](mailto:kimh.rd@mweb.co.za)

021 674 4666

084 206 2715

Editor

**Michelle Massyn**

[michellebars@yahoo.com](mailto:michellebars@yahoo.com)

082 972 9040

Graphics and layout courtesy of MDOT

[www.mdot.co.za](http://www.mdot.co.za)

## Interactions between dietary *n*-3 fatty acids and genetic variants and risk of disease

Dolores Corella<sup>1,2\*</sup> and José M. Ordovás<sup>3,4,5</sup>

<sup>1</sup>Genetic and Molecular Epidemiology Unit, School of Medicine, University of Valencia, Blasco Ibañez, 15, 46010, Valencia, Spain

<sup>2</sup>CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain

<sup>3</sup>Nutrition and Genomics Laboratory, JM-USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

<sup>4</sup>Department of Cardiovascular Epidemiology and Population Genetics, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

<sup>5</sup>Instituto Madrileño de Estudios Avanzados (IMDEA) Alimentación, Madrid, Spain

### Abstract

Nutritional genomics has undergone rapid development and the concept is now very popular with the general public. Therefore, there is increasing demand for knowledge on adapting dietary composition to the genome. Our aim has been to undertake a systematic review so as to find out the level of evidence existing on whether the effects of *n*-3 fatty acids on health can be modulated by genetic variation. A systematic literature search was conducted on studies that jointly analyse the effect of one or more genetic variants in candidate genes and *n*-3 fatty acids. Both observational and experimental studies were included. Results are classified in accordance with whether the study was undertaken on intermediate phenotypes (plasma lipid concentrations, glucose, inflammation markers, anthropometric measurements) or disease phenotypes (cancer, cardiovascular diseases, metabolic syndrome, etc) and whether it was experimental or observational. A wide diversity of genetic variants and little consistency in the publication of replication studies was found. Greater consistency was observed in studies that involved the *FADS1* and *FADS2* locus in the determination of *n*-3 fatty acid concentrations in biological samples. Most of the studies were designed to measure gene-diet interactions and not diet-gene interactions. Despite the fact that multiple studies have shown statistically significant interactions between *n*-3 fatty acids and certain genetic variants on intermediate and disease phenotypes, the individual level of evidence is very low and recommendations cannot be made on increasing or reducing the intake of *n*-3 fatty acids based on each individual's genotype.

**Key words:** Nutrigenetics: *n*-3 fatty acids: genes: cardiovascular: cancer

### Background and objectives

The effect of *n*-3 fatty acids on health has been analysed in thousands of studies throughout the last 50 years. However, there are still great discrepancies over their effects on the different intermediate and final disease phenotypes, as well as on the optimum amount of the same, or on their relationship with *n*-6 fatty acids or other components of the diet. Contributing to this divergence of results obtained in the different studies may not only be the methodological differences between studies, but also, and of great importance, the influence of genetic variability among study participants on the effects analysed. There are multiple candidate genes that may have an influence on modulating the effects of *n*-3 fatty acids on different disease phenotypes. The most relevant gene candidates will depend on the phenotype studied and,

possibly, will be different for each of them (cardiovascular disease, cancer, diabetes, neurodegenerative diseases, etc). Thus, in the era of Nutritional Genomics, it is essential to have a good knowledge of the possible relevance of genetic variability on the effects of *n*-3 fatty acid intake in order to make more individualised dietary recommendations and to obtain several, optimal effects for each individual and for each phenotype. Likewise, the study of the influence of genetic variability on certain candidate genes will contribute to a better understanding of how the *n*-3 fatty acid mechanism acts on the different disease phenotypes and how to make progress on the different pathways involved.

One of the first studies to show that the effect of a genetic variant on an intermediate phenotype of cardiovascular disease could be modulated by the amount of polyunsaturated

\*Corresponding author: D. Corella, fax +34 963864166, email dolores.corella@uv.es

fatty acids (PUFA) consumed in the diet was undertaken among participants of the Framingham Study by our research group<sup>(1)</sup>. In this study, we observed that the effect of the -75G > A polymorphism in the *APOA1* gene promoter on plasma HDL-C concentrations was modulated by total PUFA intake. Thus, when PUFA intake was low (<4% of energy), GG subjects had statistically higher HDL-C concentrations than did carriers of the A allele. Conversely, when PUFA intake was high (>8% of energy), HDL-C concentrations in carriers of the A allele were higher than those of GG subjects. This interaction was found mainly in women and was non-significant in men. Although, in that study, we did not analyse the separate effects of *n*-3 fatty acids, it did provide a setting-off point for the analysis of gene-diet interactions and for the establishment of a basic methodology for carrying out subsequent studies by our group and other research groups. Likewise, Luan *et al.*<sup>(2)</sup>, showed a gene-diet interaction between PUFA intake and intermediate phenotypes associated with obesity and insulin resistance. Specifically, they showed that the Pro12Ala polymorphism in the *PPARG2* interacted with the PUFA/saturated fatty acids (SFA) relationship of the diet in determining BMI and fasting insulin. Likewise, these investigators did not separate the different types of PUFA in their analyses. When we investigated the possible replication of this gene-diet interaction in a multiethnic Asian population, we did not find statistically significant results<sup>(3)</sup>, underscoring the need of replicating gene-diet interactions in different populations as a first step to increasing the scientific level of evidence of those findings.

In general, very few interactions have survived the replication test. Thus, limiting the clinical applicability of current findings to the design of personalized diets based on genetic information. Various factors have contributed to this, including the difficulty of accurately measuring dietary intake in observational population studies, and the lack of compliance with long-term diets in large-scale nutritional interventions. Nevertheless, the methodological quality of nutrigenomic studies has been steadily improving. Today, there is an increasing number of publications on the different fields of nutritional epidemiology in general, as well as on the study of the effects of *n*-3 fatty acids on health. In addition, '*in vitro*' studies and experimental animal models have shown that *n*-3 fatty acids influence regulation of gene expression in a number of pathways<sup>(4)</sup>, supporting the relevance of this dietary components and their genetic interactions.

### Objectives

The aim of this study was to perform a systematic review to assess the level of evidence supporting the effect of genetic variability in modulating the effects of *n*-3 fatty acids on intermediate and disease phenotypes.

### Methods

#### Criteria for considering studies for this review

**Types of studies.** This review was not restricted to randomized controlled trials, but included any epidemiological

study independently of its design, in which the interaction of *n*-3 fatty acids and any number of genetic variants has been studied in relation to intermediate and disease phenotypes. On presenting results, studies were divided into two different categories depending on the type of study: (1) Observational studies, which included both, cross-sectional studies as well as case-control and cohort studies and (2) Intervention studies, which included studies in which a dietary intervention was undertaken and where the contribution of *n*-3 fatty acids was studied. Both controlled and uncontrolled studies, with or without randomization were analysed. There was no restriction on language, publication type and sample size.

**Types of participants.** There was no restriction on the basis of gender, age, ethnicity, study setting or other characteristics of participants. Studies undertaken on a general healthy population as well as studies that involve different types of patients with certain intermediate or final disease phenotypes were included. On analysing each study, the sample type is indicated in order to ensure the homogeneity of comparisons.

**Types of *n*-3 fatty acid measurements.** All observational or intervention studies in which a measurement of the *n*-3 fatty acid intake contributed by diet (total or separated as LC *n*-3 fatty acids (LC *n*-3 fatty acids), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA) or others was undertaken by means of the different types of diet questionnaires, including semiquantitative food frequency questionnaires (FFQ), 24-h recalls or dietary records, were included. Also included were those studies that measured total or specific *n*-3 fatty acids on different kinds of biological samples (subcutaneous fat, erythrocytes, plasma, breast milk or serum). There is an excellent review on the validity of each of these methods for correctly measuring *n*-3 fatty acids in different situations<sup>(5)</sup>. This review concludes that the summarised quality of *n*-3 fatty acid estimates derived from FFQ is good or acceptable according to the (EUROpean micronutrient RECommendations Aligned) EUR-RECA scoring system and that no dietary intake method is superior to any other. With regard to measurements of *n*-3 fatty acids in different biological samples, the literature describes subcutaneous fat as the best reference method. We also included all intervention studies in which *n*-3 fatty acids were administered under various preparations (enriched foods, oils, pills, etc).

**Types of genetic variants.** Any study that reported one or more genetic variants of any kind [single nucleotide polymorphisms (SNP), insertions, deletions, copy number variations (CNV)] were included. Haplotypes as well as combined analysis of genetic variant were also included.

**Types of outcome measures.** All types of diseases were included, both disease phenotypes (cancer, cardiovascular diseases, neurodegenerative diseases, metabolic syndrome, diabetes, etc), and intermediate disease phenotypes (plasma lipids, plasma glucose and insulin, anthropometric measures, inflammation markers, etc).

### Search methods for identification of studies

A systematic literature search was performed in April 2011. The literature search was conducted in the following databases: Medlars Online International Literature (MEDLINE), via PubMed<sup>®</sup>; EMBASE<sup>®</sup>; and Latin American and Caribbean Health Sciences Literature (LILACS). We first searched in MEDLINE (from 1966 to 2011) using common medical subject heading (MESH) terms and adapted for use in other databases. The following terms were used: *n*-3 or *n*-3 fatty acid or *n*-3 fatty acids; or *n*-3 or *n*-3 fatty acids; or polyunsaturated fatty acid or polyunsaturated fatty acids; or unsaturated fatty acids or essential fatty acids; or alpha-linolenic acid or ALA; or eicosapentanoic acid or EPA; or docosahexanoic acid or DHA; or docosapentanoic acid or DPA; or alpha-linolenic acid or ALA or long chain fatty acids. These terms were combined in the search with the genetic terms in order to find studies that analyse the genetic influence on the effects of *n*-3 fatty acids. The genetic terms used were: genes; or genetic variants; or gene variants; or gene variant; or polymorphisms. Furthermore, as several of the studies found using those key words were carried out on animals, plants or in vitro, another term was added to the search to further limit the studies. The term added was 'human/s'.

### Processing of articles

Initial screening of articles was undertaken on the basis of abstracts. If it was clear from the abstract that the article did not meet the inclusion criteria, it was rejected. Titles and abstracts were screened by both authors for inclusion based on study design, *n*-3 fatty acids assessment, genetic analysis and outcome measures. The full text of the selected article was retrieved so as to analyse the complete information. Full text articles were also searched for any further relevant publications. Both authors extracted data from the studies and study details were summarised in tables or in text. Although there are various study quality indicators that could be applied, we have opted, in this review, not to apply them for including or excluding a study, as this is a time consuming process and what we wanted at the onset was to have a wide vision of the studies undertaken that had analysed the genetic influence on the multiple effects of *n*-3 fatty acids on health. Nevertheless, in the review and information gathering process, the authors have taken into account whether the study fulfils the minimum quality indicators, making a comment on the study when some limitation is detected (reduced sample size, lack of adjustment for potential confounders, poor quality of genetic analysis, etc).

### Results

From the various search terms introduced, the widest number of articles was found with the 'PUFA and genes' combination. This search resulted in 5674 papers. However, the screening of the abstracts showed that it was too general a search as in it were included all types of PUFA and not only *n*-3. Restricting the search to the terms '*n*-3 fatty acids and genes' resulted in

670 papers. The screening of those abstracts revealed that the search was still too wide, as it included studies of all kinds on animals, plants, cultivated cells, etc., so the term 'humans' was added, resulting in 150 papers. As the term 'genes' is also non-specific, as it includes studies of all kinds in which analyses of expression, regulation, etc were carried out, the search was narrowed by adding the term 'gene variants' or 'genetic variants'. This selection turned out to be too restrictive, as only twenty-five papers were found. Having tested various strategies of search term combinations, it was observed that the term 'polymorphism', is more suitable than 'genetic variant', as it results in a greater number of papers that fulfil the inclusion criteria of focusing on epidemiological studies that simultaneously analyse the effect of genetic variants and *n*-3 fatty acids on intermediate or final disease phenotypes. Sixty papers were obtained in this way. Of which fifteen were discarded for being reviews or for not studying the theme even though they had been selected by the aforementioned key words indicated. In addition, the reference lists of the selected articles were scanned, which resulted in another four original publications for inclusion.

### Influence of genetic variants in *n*-3 fatty acids concentration in different biological samples

On analysing the literature on the influence of the different genetic variants on the effects of *n*-3 fatty acids in intermediate and disease phenotypes, we noted that in recent years various articles have been published showing several highly consistent effects of certain genetic variants, namely at desaturases loci, on PUFA concentrations in different tissues. We believe that these genetic variants may be very important in further studies, so we began first of all to analyse the effects of those variants. The delta-6 desaturase (D6D) and delta-5 desaturase (D5D) are membrane-bound enzymes that catalyze the rate-limiting formation of LC PUFA. D6D catalyzes the conversion of ALA (18:3*n*-3) and linoleic acid (LA, 18:2*n*-6) into stearidonic acid (STD, 18:4*n*-3) and  $\gamma$ -linolenic acid (GLA, 18:3*n*-6), respectively. D5D catalyzes the conversion of eicosatetraenoic acid (ETA, 20:4*n*-3) and dihomo- $\gamma$ -linolenic acid (DGLA, 20:3*n*-6) into EPA (20:5*n*-3) and arachidonic acid (AA, 20:4*n*-6), respectively<sup>(6,7)</sup>. The desaturase-encoding genes (*FADS1* for D5D and *FADS2* for D6D) form a gene cluster on chromosome 11 together with a third desaturase gene, *FADS3*, of lesser known function. The first epidemiological study in which a significant association was shown between variation in that cluster and PUFA concentrations was carried out by Schaeffer *et al.*<sup>(8)</sup> on 727 Germans of the European Community Respiratory Health Survey I. After analysing eighteen SNP, they found that eleven of them presented highly significant associations with the concentrations of various PUFA in serum phospholipids. Thus, carriers of the minor alleles at several SNP (rs174544, rs174553, rs174556, rs174561, rs3834458, rs968567, rs99780, rs174570, rs2072114, rs174583, or rs174589) had enhanced levels of the precursor PUFA with two or three double bonds and reduced levels of LC-PUFA with  $\geq 4$  double bonds and major product-to-substrate

ratios of the *n*-6 pathway (AA-to-LA ratio) and the *n*-3 pathway (EPA-to-ALA ratio).

Interestingly, fatty acids belonging to other pathways like oleic acid and DHA, whose source is mainly nutritional, did not show significant associations with those genetic variants. Subsequent studies have consistently replicated the associations between polymorphisms in the *FADS1* and *FADS2* genes and PUFA concentration measurements in different biological samples including breast milk<sup>(9–18)</sup>. In the excellent review on this subject undertaken by Lattka *et al.*<sup>(19)</sup>, those studies indicating the SNP analysed and the fatty acids for which an association has been found in different tissues are presented in detail. These associations between the *FADS1/FADS2* cluster and PUFA concentrations have also been confirmed in genome wide association studies (GWAs)<sup>(20)</sup>. Other GWAs have also reported associations between the *FADS1/FADS2* cluster and plasma lipid concentrations<sup>(21,22)</sup>.

Therefore, it will be informative to accumulate additional evidence related to the most relevant polymorphisms in *FADS1* and *FADS2* in future studies seeking to analyse the influence of *n*-3 fatty acids on disease, as the overall concentrations of *n*-3 fatty acids will not depend only on intake, but will also be modulated by these genetic variants. However, bearing in mind that the discovery of the importance of these polymorphisms is recent, most of the studies undertaken that have focused on genetic variants have not analysed them, so we do not have the full data. There are, however, several recent studies that have studied the influence of genetic variants in *FADS1* and *FADS2* as modulators of the effects of dietary *n*-3 fatty acids on various phenotypes that is summarised in the corresponding tables depending on the study design.

To organise the presentation of results and bearing in mind that we have not selected a specific disease but all phenotypes that have been researched, we will first consider the study type, whether it is an observational or experimental study. As most studies are observational, within them we will consider whether they have studied intermediate or disease phenotypes so as to present them in different tables. Intervention studies will be analysed jointly.

#### *Interaction between n-3 fatty acids and genetic variants in determining intermediate disease phenotypes in observational studies*

One of the first studies to separately study the effects of *n*-3 and *n*-6 fatty acids in modulating the effects of a genetic variant on an intermediate cardiovascular risk phenotype was carried out by our research group on participants in the Framingham Study<sup>(23)</sup>. Regulation of gene expression by PUFA can occur through interaction with specific or non-specific ligands. Specifically, it has been shown that PUFA can interact directly with transcription factors such as peroxisome proliferator-activated receptor  $\alpha$  (PPAR $\alpha$ ), a nuclear transcription factor that regulates multiple genes involved in lipid homeostasis. One genetic variant in the *PPARA* gene, consisting of a G484C transversion at the codon 162, creates a missense mutation that alters leucine to valine (L162V) and has functional consequences on receptor activity depending on the

concentration of the ligand. PUFA are natural ligands of PPAR $\alpha$  and, therefore, their concentration can increase or reduce the gene expression of the *PPARA* gene, which in turn modulates multiple genes. In the Framingham Study we found a statistically significant interaction between the L162V polymorphism and dietary PUFA intake in determining plasma triglycerides and apoC-III concentrations (Table 1)<sup>(23–34)</sup>. For both parameters, those with the 162V allele had lower concentrations of TG and apoC-III with higher intake of PUFA. In contrast, among homozygotes for the 162L allele, PUFA intake did not decrease either TG or apoC-III concentrations. We also explored the effect of *n*-3 and *n*-6 fatty acids and found an effect similar for both. Later, Chan *et al.*<sup>(24)</sup> attempted to study this interaction in Chinese, Malays and Asian Indians participating in the 1998 Singapore National Health Survey. However, they found that the L162V variant was not polymorphic in the Asian population. Therefore, their genetic analysis focused on the V227A variant which is common among Asians, but not in Caucasian populations. Although they did not analyse the effects of *n*-3 and *n*-6 fatty acids separately, a statistically significant interaction was found between the V227A polymorphism and dietary PUFA in HDL-C concentrations in Chinese women. Even though this interaction may have been observed in a different phenotype, it contributes to supporting the hypothesis that the effects of the variation in the *PPARA* gene are modulated by PUFA. Some years later, Volcik *et al.*<sup>(25)</sup> evaluated the influence of *PPARA* genetic variation on the association between PUFA intake (specifically *n*-6 and LC *n*-3 fatty acids) and plasma lipid concentration in the biethnic Atherosclerosis Risk in Communities (ARIC) Study. Although they found no significant interactions between the *PPARA* L162V polymorphism and plasma lipids, they did find an interaction with the 3'UTR C  $\rightarrow$  T SNP polymorphism in the same gene. Being a biethnic population, factors related with the different prevalence or relevance of certain genetic variants between populations may have had an influence on the results.

In addition to these observational studies, an intervention study in which the PUFA/SFA ratio was modified in the diet, concluded that the L162V in the *PPARA* gene significantly contributes to modulating the different response observed among individuals<sup>(35)</sup>. In a more detailed way, Rudkowska *et al.*<sup>(36)</sup> showed that *n*-3 fatty acids regulate gene expression levels differently in subjects carrying the *PPARA* L162V polymorphism. These authors also examined the effects of *n*-3 fatty acids on LPL activity taking into consideration the presence of the *PPARA* L162V polymorphism, and observing that *n*-3 fatty acids increase the transcription rate of LPL to a greater extent in L162-*PPARA* than V162-*PPARA* alleles<sup>(37)</sup>. All of this contributes to increasing the evidence that the effects of *n*-3 fatty acids on plasma triglyceride concentrations and related measures are modulated by the *PPARA* gene variation. However, the level of evidence is still insufficient to be able to make dietary recommendations on *n*-3 fatty acid intake based on the determination of this polymorphism.

Whereas most of the previous gene-PUFA interactions related to plasma lipids focused on *PPARA*, there has been a current shift towards other genes, including the *FADS* genes.

**Table 1.** Observational studies analyzing *n*-3 fatty acids and genetic variants in determining intermediate phenotypes

Reference	Study population	Phenotype	Genetic variant (s)	Interaction	Main results
Tai <i>et al.</i> <sup>(23)</sup>	Cross-sectional study in participants in the Framingham Offspring Study (1003 men and 1103 women)	Plasma triglycerides and apoC-III concentrations	<i>PPARA</i> (L162V polymorphism)	Yes <i>PPARA</i> L162V and <i>n</i> -3 fatty acids on plasma apoCIII concentrations	Carriers of the 162V allele had significantly lower plasma triglycerides and apoC-III concentrations when consuming a high PUFA diet, in which <i>n</i> -3 and <i>n</i> -6 fatty acids seem to have a similar role.
Chan <i>et al.</i> <sup>(24)</sup>	Cross-sectional study among Participants in the 1998 Singapore National Health Survey: 1964 men (1318 Chinese, 364 Malays and 282 Asian Indians) and 2284 women (1581 Chinese, 397 Malays and 306 Asian Indians)	Plasma lipids	<i>PPARA</i> (V227A polymorphism)	Yes <i>PPARA</i> V227A and PUFA on HDL-C concentrations	In carriers of the A227 allele, increasing PUFA intake was associated with lower HDL-C concentrations. In those who were homozygous for the common allele, this association was much weaker
Volcik <i>et al.</i> <sup>(25)</sup>	Cross-sectional study among participants in the biethnic Atherosclerosis Risk in Communities (ARIC) Study (10 134 whites and 3480 African Americans)	Plasma lipids	<i>PPARA</i> (L162V and 3'UTR C → T polymorphisms)	Yes <i>PPARA</i> 3'UTR C → T SNP and long-chain <i>n</i> -3 fatty acids on LDL-C	A significant interaction between the <i>PPARA</i> 3'UTR C → T SNP and LC <i>n</i> -3 fatty acids on total cholesterol and LDL-C concentrations in African American participants. No significant interaction with the <i>PPARA</i> L126V SNP.
Lai <i>et al.</i> <sup>(26)</sup>	Cross-sectional study among participants in the Framingham Offspring cohort (1001 men and 1147 women)	Plasma lipids, remnant-like particle concentrations, and lipoprotein particle size	<i>APOA5</i> SNP: -1131T > C, -3A > G, IVS3 + 476G > A, and 1259T > C and 56C > G	No with <i>n</i> -3 fatty acids	Significant gene-diet interactions between the -1131T > C polymorphism and total PUFA intake were found in determining fasting triglycerides, remnants and particle size. However, the PUFA- <i>APOA5</i> interactions were specific for dietary <i>n</i> -6 fatty acids. No significant interaction with <i>n</i> -3 fatty acids were found
Verduci <i>et al.</i> <sup>(27)</sup>	Cross-sectional study in obese children (53 girls and 68 boys)	Plasma adiponectin and HOMA-IR	<i>ADIPOQ</i> gene (SNP 276G > T)	Yes <i>ADIPOQ</i> polymorphism and <i>n</i> -6/ <i>n</i> -3 LC-PUFA	In obese children, carriers of the SNP 276G > T may be at increased risk of metabolic complications compared with noncarriers, possibly due in part to the <i>n</i> -6/ <i>n</i> -3 LC-PUFA ratio in phospholipids
Ylönen <i>et al.</i> <sup>(28)</sup>	Cross-sectional study among 571 non-diabetic relatives of subjects with type II diabetes.	Plasma glucose and IR	<i>PPARG2</i> (Pro12Ala SNP)	Yes Pro12Ala and intake of <i>n</i> -3	The <i>PPARG</i> polymorphism modulate the associations marine <i>n</i> -3 fatty acids with glucose metabolism and fasting free fatty acids
Lu <i>et al.</i> <sup>(29)</sup>	Cross-sectional investigation in the Doetinchem Cohort Study (3575 subjects)	Plasma lipids	<i>FADS</i> cluster (rs174546, rs482548, and rs174570 polymorphisms)	Yes rs174546 polymorphism and <i>n</i> -3 PUFA intake	Significant associations between rs174546 genotypes and total and non-HDL-cholesterol concentrations in the group with a high intake of <i>n</i> -3 PUFA but not in the low intake group
Kim <i>et al.</i> <sup>(30)</sup>	Cross-sectional study in Koreans (580 men, 614 women).	Serum phospholipids, adiponectin, HOMA-IR	<i>ADIPOQ</i> : (-11391G > A; -11377C > G; H241P; Y111H; G90S; R221S; 45T > G; 276G > T polymorphisms)	No with <i>n</i> -3	The 276G carriers with a higher proportion of 18:2n6 exhibited more pronounced IR characteristics. No interaction with <i>n</i> -3 was observed
Zhou <i>et al.</i> <sup>(31)</sup>	Cross-sectional study in Chinese (195 men and 386 women). Erythrocyte membrane fatty acids were measured	Inflammatory markers	<i>IL-6</i> (-572 C > G polymorphism)	Yes ( <i>IL-6</i> genotype and <i>n</i> -3 levels in males)	Erythrocyte <i>n</i> -3 PUFA intake modulated the effects of <i>IL-6</i> -572 genotype on HDL-c concentrations in males but not in females

Interactions between dietary *n*-3 fatty acids and genetic variants

**Table 1.** Continued

Reference	Study population	Phenotype	Genetic variant (s)	Interaction	Main results
Enzenbach <i>et al.</i> <sup>(32)</sup>	Cross-sectional study in 1980 participants of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort	CRP and adiponectin	<i>PARG2</i> (Pro12Ala polymorphism)	No	Erythrocyte PUFA are related to circulating CRP and adiponectin. However, these associations were not modified by the <i>PARG2</i> Pro12Ala polymorphism
Huang <i>et al.</i> <sup>(33)</sup>	Cross-sectional study in 995 participants in the Boston Puerto Rican Health Study	Plasma homocysteine concentrations	<i>MTHFR</i> (1298A > C and 677C > T polymorphisms)	Yes	Dietary <i>n</i> -3 fatty acids modulate the effect of the <i>MTHFR</i> variants on plasma homocysteine. Participants with combined genotypes of both SNP who consumed high levels of <i>n</i> -3 PUFA had lower plasma homocysteine.
Richardson <i>et al.</i> <sup>(34)</sup>	Cross-sectional study in two replication cohorts: The Framingham study (1259 men and 1352 women) and the GOLDN Study (481 men and 513 women)	Anthropometrics, lipids and glucose	Seven SNP in the <i>PLIN4</i> gene: rs884164, rs1609717, rs7250947, rs8887, rs8102428, rs892158, and rs11673616.	Yes	<i>n</i> -3 fatty acids modulate the associations between the rs8887 SNP and anthropometrics. rs884164 showed interaction with both <i>n</i> 3 and <i>n</i> 6 PUFA modulating anthropometric and lipid phenotypes.

PPARA: Peroxisome Proliferator-Activated Receptor; alpha; APOA5: apolipoprotein A-V; ADIPOQ: Adiponectin; PARG2: Peroxisome Proliferator-Activated Receptor-γ2; FADS: fatty acid desaturase; IL-6: interleukin-6; MTHFR: Methylene tetrahydrofolate reductase; PLIN4: perilipin 4.

Table 1 also provides a summary of the other studies found during this review that analyse the interaction between *n*-3 fatty acid levels and intermediate disease phenotypes including plasma lipids, anthropometric measurements, insulin resistance and inflammatory markers. Of all of them, we would like to mention in particular and because of its latest findings involving microRNAs (short post-transcriptional regulators that bind to complementary sequences in the 3'UTR of multiple target mRNAs, usually resulting in their silencing), the study recently published by Richardson *et al.*<sup>(34)</sup>. The authors found significant interactions between the rs8887 minor allele in the perilipin 4 (*PLIN4*) gene with the *n*-3 fatty acid intake modulating anthropometrics. Moreover, *in silico* analysis of the *PLIN4* 3'UTR sequence surrounding the rs8887 minor allele predicted a seed site for the human microRNA-522 (miR-522). In vitro results suggested that the interaction with PUFA acts in part through creation of a miR-522 regulatory site.

*Interaction between n-3 fatty acids and genetic variants in determining disease phenotypes in observational studies*

In this section, we have reviewed the studies that analyse the influence of the *n*-3 fatty acids, either originating from the diet or through their measurement in biological samples and different disease phenotypes (Table 2)<sup>(38–47)</sup>. We have considered disease phenotypes to be the different types of cardiovascular disease (coronary heart disease, stroke), cancer (breast, lung, colo-rectal, prostate), metabolic syndrome, diabetes, etc.

Various studies have been carried out that have investigated the interaction between intake of *n*-3 fatty acids and the risk of different types of cancer. The primary working hypotheses was that marine *n*-3 fatty acids may provide protection against breast cancer, as shown in previous experimental studies. It is, moreover, hypothesized that the inter-individual differences in the ability to protect cells from cytotoxic lipid peroxidation products may determine the protective effect of marine *n*-3 fatty acids on breast cancer. The glutathione S-transferases (GST) are potential major catalysts in the elimination of these beneficial by-products. These enzymes are polymorphic and many of them have been studied in relation with different types of cancer, hence the great importance currently placed on them as modulators of cancer risk faced with different environmental exposures<sup>(48)</sup>. There are three well-characterized isozymes, *GSTM1*, *T1*, and *P1*, in which polymorphisms have been extensively studied with respect to DNA adducts and cancer. Gago-Dominguez *et al.*<sup>(38)</sup> hypothesized that women possessing low activity GST genotypes (*GSTM1* null, *GSTT1* null and *GSTP1* AB/BB) might exhibit a stronger marine *n*-3 fatty acid–breast cancer inverse association than those possessing the high activity genotypes. To check this hypothesis, they undertook a nested case-control study among the participants in the Singapore Chinese Health Study, a population-based, prospective investigation of diet and cancer risk. At recruitment (from April 1993 to December 1998), information on usual diet over the last year was obtained by a semi-quantitative food frequency questionnaire. In 2002,

**Table 2.** Observational studies analyzing *n*-3 fatty acids and genetic variants in determining disease phenotypes

Reference	Study population	Phenotype	Genetic variant(s)	Interaction	Main results
Gago-Dominguez <i>et al.</i> <sup>(38)</sup>	Nested case-control study in women in the Singapore Chinese Health Study, a population-based, prospective investigation of diet and cancer risk	Breast cancer incidence	Glutathione S-transferases (GST) genotypes ( <i>GSTM1</i> null, <i>GSTT1</i> null and <i>GSTP1</i> AB/BB)	Yes ( <i>GSTP1</i> and quartiles of marine <i>n</i> -3)	Women with genetic polymorphisms encoding lower or no enzymatic activity of <i>GSTM1</i> , <i>GSTT1</i> and/or <i>GSTP1</i> experienced more breast cancer protection from marine <i>n</i> -3 fatty acids than those with high activity genotypes
Hedelin <i>et al.</i> <sup>(39)</sup>	Population-based case-control study of prostate cancer (n = 1,499 cases and 1,130 controls) in Sweden	Prostate cancer	<i>COX-2</i> gene: rs2745557, rs20432, rs4648276, rs5275 and rs689470	Yes <i>COX-2</i> gene (rs5275 SNP) and salmon-type fish intake	The association between marine fatty acids and the risk of prostate cancer was modified by genetic variation in the <i>COX-2</i> gene. Strong inverse associations with increasing intake of salmon-type fish only observed among carriers of the variant allele of the rs5275.
Fradet <i>et al.</i> <sup>(40)</sup>	Case-control study (n = 506 aggressive incident prostate cancer cases and 506 controls) in Cleveland, USA	Prostate cancer	<i>COX-2</i> gene: rs689466, rs20417, rs2745557, rs5277, rs2066826, rs5275, rs2206593, rs689470, and rs4648310	Yes <i>COX-2</i> gene (rs 4648310 SNP) and LC <i>n</i> -3 fatty acids intake	The inverse association between LC <i>n</i> -3 fatty acids and the risk of aggressive prostate cancer was modified by genetic variation in the <i>COX-2</i> gene. Strong protective association among carriers of the rs 4648310 variant allele.
Stern <i>et al.</i> <sup>(41)</sup>	Case-control study (n = 753 cases and 799 controls) in a study of risk factors in USA	Colo-rectal cancer	<i>XRCC1</i> -194, <i>XRCC1</i> -399 and <i>XRCC3</i> -241	Yes <i>XRCC1</i> gene and <i>n</i> -6/ <i>n</i> -3 ratio	The effect of the <i>XRCC1</i> polymorphisms on colo-rectal cancer risk is modulated by the <i>n</i> -6/ <i>n</i> -3 ratio. A high <i>n</i> -6/ <i>n</i> -3 ratio increased the risks in subjects carrying the <i>XRCC1</i> Trp 194 allele or the Arg 399 allele
Stern <i>et al.</i> <sup>(42)</sup>	Nested case-control study in the Singapore Chinese Health Study (310 cases and 1,176 controls)	Colo-rectal cancer	<i>XRCC1</i> : rs1799782 and rs25487. <i>PARP</i> : rs1136410), and rs3219145. <i>OGG1</i> : rs1052133; <i>XPD</i> : rs1799793 and rs13181	Yes <i>PARP</i> gene (rs1136410) and marine <i>n</i> -3 PUFA	The <i>PARP</i> Val762Ala SNP modified the association between marine <i>n</i> -3 PUFA and rectal cancer risk, with no evidence of interaction among colon cancer. Carriers of the 762Ala allele have higher rectal cancer risk with a high intake of marine <i>n</i> -3 PUFA.
Guerreiro <i>et al.</i> <sup>(43)</sup>	Case-control study in 116 controls and 99 patients with Crohn's disease	Crohn's disease and pro- and anti-inflammatory cytokines	Seven SNP in the <i>IL1</i> , <i>TNFA</i> , <i>LTA</i> , and <i>IL6</i> genes	Yes <i>TNFA</i> and <i>n</i> -3 PUFA	Low intake of <i>n</i> -3 PUFA and high <i>n</i> -6/ <i>n</i> -3 PUFA ratio in patients with the <i>TNFA</i> 857 polymorphism were associated with higher disease risk
Martinelli <i>et al.</i> <sup>(44)</sup>	Case-control study in the Verona Heart Study (610 cases of angiographically documented CAD and 266 controls)	Angiographically proven coronary artery disease. Inflammatory markers	Thirteen SNP tagging the greatest variability of the <i>FADS</i> gene region	Yes <i>FADS</i> genotypes and erythrocyte PUFA	Haplotypes of the <i>FADS</i> gene cluster, including variants associated with an elevated AA/LA, were also associated to both a higher hs-CRP concentration and greater risk of coronary artery disease. This was modulated by the the ratio of AA to LA on erythrocytes.
Dwyer JH <i>et al.</i> <sup>(45)</sup>	Cohort of 470 healthy, middle-aged women and men from the Los Angeles Atherosclerosis Study	Carotid-artery intima-media thickness, and markers of inflammation	<i>5-LO</i> genotypes	Yes <i>5-LO</i> and <i>n</i> -3	Increased dietary arachidonic acid significantly enhanced the apparent atherogenic effect of the <i>5-LO</i> genotype, whereas increased intake of <i>n</i> -3 fatty acids blunted the effect.

Table 2. Continued

Reference	Study population	Phenotype	Genetic variant(s)	Interaction	Main results
Phillips <i>et al.</i> <sup>(46)</sup>	Case-control study in LIPGENE-SU.VI.MAX study of metabolic syndrome cases and matched controls (n = 1754)	Metabolic syndrome	C3 polymorphisms (rs11569562, rs2250656, rs1047286, rs2230199, rs8107911, rs344548, rs344550, rs2241393, rs7257062, rs163913, and rs2230204), LEPR: rs10493380	Yes C3 rs11569562 polymorphism and plasma n-3	A high n-3 plasma concentration may modulate the increased susceptibility to metabolic syndrome that is conferred by C3 polymorphisms
Phillips <i>et al.</i> <sup>(47)</sup>	Case-control study in LIPGENE-SU.VI.MAX study of metabolic syndrome cases and matched controls (n = 1754)	Metabolic syndrome and insulin resistance	LEPR: rs10493380, rs1137100, rs1137101, rs12067936, rs1805096, rs2025805, rs3790419, rs3790433, rs6673324, and rs8179183)	Yes LEPR n-3 and n-6 PUFA	Homozygosity for the LEPR rs3790433 G allele was associated with insulin resistance. This genetic influence was more evident in individuals with low plasma n-3 or high n-6.

GSTM1: Glutathione S-transferase Mu 1; GSTT1: glutathione S-transferase theta 1; glutathione S-transferase pi 1; COX-2: Cyclooxygenase-2; XRCC1: X-ray repair cross-complementing protein 1; XRCC3: X-ray repair complementing defective repair in Chinese hamster cells 3; PARP: Poly ADP-ribose polymerase; OGG1: Oxoguanine glycosylase 1; XPD: xeroderma pigmentosum group D; TNF- $\alpha$ : Tumor necrosis factor; IL-6: Interleukin-6; LTA: lymphotxin  $\alpha$ ; FADS: fatty acid desaturase; 5-LO: arachidonate 5-lipoxygenase; C3: complement component 3; LEPR: Leptin receptor.

they identified 399 cases of incident breast cancer among female cohort subjects. Of those cases, they were only able to carry out a genetic analysis on 258 cases. For marine n-3 fatty acid intake, subjects were categorized based on quartile distribution values among females. They examined the association between n-3 fatty acids and breast cancer stratified by *GSTM1*, *GSTT1* and *GSTP1* genotypes and found a stronger protection of the n-3 fatty acids in the low than high activity genotype subgroups. Thus, the risk of breast cancer in high (quartiles 2–4) v. low (quartile 1) consumers of marine n-3 fatty acids, was reduced by half in women with the genotype *GSTP1* AB/BB genotype ( $P < 0.05$ ), achieving similar results on the limit of statistical significance for the other genotypes. The authors concluded that the Chinese women carriers of the genetic polymorphisms encoding lower or no enzymatic activity of *GSTM1*, *GSTT1* and/or *GSTP1* experienced more breast cancer protection from marine n-3 fatty acids than those with high activity genotypes, this being the first study to report that association. It has not been possible to replicate these results in subsequent studies, so the level of evidence of the interaction between these polymorphisms and marine n-3 fatty acids on the incidence of breast cancer remains low.

Continuing with the premise that a high intake of n-3 fatty acids, especially LC fatty acids (EPA and DHA) can protect against prostate cancer, and in order to gain better understanding about their mechanisms and the potential genetic influence, Hedelin *et al.*<sup>(39)</sup>, carried out a population-based case-control study in Sweden. Bearing in mind that one of the proposed mechanisms by which n-3 fatty acids may affect carcinogenesis is through their suppressive effect on the biosynthesis of eicosanoids derived from arachidonic acid, cyclooxygenase-2 (*COX-2*), a key enzyme in eicosanoid synthesis, overexpressed in prostate cancer tissues, it may play a very important role. Therefore, the *COX-2* gene could be important in modulating the effect of the n-3 fatty acids on the risk of prostate cancer. To test this hypothesis, they analysed 5 polymorphisms in the *COX-2* gene in participants of the Cancer Prostate in Sweden Study. Fish consumption and the intake of n-3 fatty acids were measured through a validated FFQ. They found no association between total intake of n-3 fatty acids and prostate cancer risk, but did find an inverse association between fatty fish consumption and the risk of prostate cancer. They only found a statistically significant interaction between salmon-type fish intake or combined intake of salmon/herring/mackerel and the *COX-2* +6365 T/C polymorphism. Thus, among subjects who were heterozygous or homozygous for the variant allele (C), high intake of salmon-type fish was associated with a significantly decreased risk of prostate cancer (OR for once per week or more v. never = 0.28, 95% CI 0.18, 0.45). No association was found in carriers of the major allele.

Interestingly, the results of this study have been partially replicated by others, so increasing the consistency level of the interaction between n-3 fatty acids and the *COX-2* gene polymorphisms. Fradet *et al.*<sup>(40)</sup> in a case-control study that included aggressive prostate cancer cases in Cleveland, USA, assessed n-3 fatty acid intake through a FFQ and genotyped nine polymorphisms in the *COX-2* gene. They found that an increased intake of LC n-3 was strongly associated with a

decreased risk of aggressive prostate cancer, as well as a statistically significant interaction between the LC *n*-3 fatty acid intake and a *COX-2* polymorphism (SNP rs4648310), so that in men with this variant SNP, the association of the LC *n*-3 fatty acids with lower risk of prostate cancer was very strong.

Fradet *et al.*<sup>(40)</sup> did not find a similar pattern of interaction with rs5275. The SNP rs4648310 and rs5275 are located 2.4 kb apart and have weak linkage disequilibrium among Whites. The functional effect of each one of these variants on *COX-2* activity is not yet known. However, the combined findings of Fradet *et al.*<sup>(40)</sup> and Hedelin *et al.*<sup>(37)</sup> support the hypothesis that the effect of LC *n*-3 fatty acids on the risk of prostate cancer may be modified by *COX-2* genetic variation.

On the other hand, persistent oxidative stress and oxidative damage to the colon epithelium seem to play an important role in colorectal cancer. Polymorphisms in genes involved in the fatty acids-DNA damage/repair pathway, therefore, may play a role in determining the effects of fatty-acids in causing DNA damage and subsequent colon cancer risk. *XRCC1* (X-ray repair cross-complementing protein 1) and *XRCC3* (X-ray repair complementing defective repair in Chinese hamster cells 3) are involved in the efficient repair of DNA and may play an important role in the repair or modulation of the effects of PUFA intake on cancer colo-rectal cancer risk. Stern *et al.*<sup>(41)</sup> studied the effect of some polymorphisms in the *XRCC1* and *XRCC3* genes as unsaturated fatty acids effect modifiers on colo-rectal cancer risk in the USA. The *XRCC1*-194, *XRCC1*-399 and *XRCC3*-241 polymorphisms were determined. The ratio of dietary *n*-6/*n*-3 fatty acids was calculated. Although they did not find significant interactions between the polymorphisms and total PUFA intake on cancer risk, they found a significant interaction between the omega-6/*n*-3 ratio and the *XRCC1* genotypes on colo-rectal cancer risk. Subjects with the *XRCC1* Trp 194 allele or the Arg 399 allele seem to have a higher risk of colorectal adenomas when ratio is high. No evidence of an *XRCC3*-241 effect modification on the effect of high intake ratios was observed. Bearing in mind that this is the first study to report a significant interaction between the *n*-6/*n*-3 fatty acid ratio and the risk of colo-rectal cancer, further studies are required to confirm the results. Moreover, many more genes other than the *XRCC1* and the *XRCC3* play a role in the fatty acids-DNA damage/repair pathways. Thus, the simultaneous analysis of all relevant genes in the complex pathway will be useful in understanding these interactions better. Along these lines, Stern *et al.*<sup>(42)</sup> carried out another nested case-control study on Chinese participants in the Singapore Chinese Health Study. 7 SNP in various DNA repair genes: *XRCC1*, Poly (ADP-ribose) polymerase (*PARP*), Oxoguanine glycosylase 1 (*OGG1*), and xeroderma pigmentosum group D (*XPD*) were analyzed. The authors reported that the *PARP* Val762Ala SNP modified the association between marine *n*-3 fatty acids and rectal cancer risk, with no evidence of interaction with colon cancer. A high intake of marine *n*-3 fatty acids notably increases cancer risk in 762-Ala allele carriers. The *PARP* protein plays an important role in maintaining genomic stability, apoptosis, and regulating transcription. The mechanism through which greater marine *n*-3

fatty acids could increase cancer risk in carriers of this genetic variant is not fully understood, but the fact that the authors have not found this same effect in total *n*-3 fatty acid intake suggests that the association must be mainly due to the LC EPA and DHA. In addition to cancer, several statistically significant interaction between *n*-3 fatty acids and genetic variants in determining other disease phenotypes have been found (metabolic syndrome, cardiovascular diseases, etc)<sup>(43–47)</sup>. These studies are also summarized in Table 2.

### Interaction between *n*-3 fatty acids and genetic variants in determining intermediate and disease phenotypes in intervention studies

Table 3<sup>(49–54)</sup> provides a summary of the main characteristics of intervention studies based on changes in food patterns, or addition of specific food or dietary supplement, all aimed to provide different levels of *n*-3-fatty acids. Given the large diversity of results and genotypes analysed, firm conclusions cannot be established. Intervention studies are few and far between and often carried out on small populations, so new intervention studies on larger samples and over longer periods of time are required.

Although intervention studies provide a higher level of scientific evidence than observational studies, they are more complex to undertake, especially on large samples. One of the limitations of most of the intervention studies carried out to date has been the fact that the sample size is small and the groups of the different genotypes have been heterogeneous in size because the studies were not basically designed to investigate the effect of a genetic variant or previously selected genetic variants, but to first undertake the intervention and then genotype the individuals. One proposal for improving this would be to undertake a priori the choice of the main genetic variants to be studied and select individuals for their genotype (either by a genetic variant or by a combination of relevant genetic variants) and include the individuals in the study depending on their genotype in order to form groups of similar size and with an adequate statistical power. We should incorporate better markers of dietary intervention compliance and discard individuals who do not comply with the intervention instead of analyzing 'intention to treat' data. Furthermore, it would be necessary to propose a parallel sample of replication in order to check the replication of results in different individuals from the same population and so increase internal validity. Later studies would also be required in order to confirm the external validity of the results in other populations.

### Conclusions

There are scores of studies showing statistically significant interactions between *n*-3 fatty acid intake and/or their concentrations in different biological samples and various genotypes, resulting in differing effects of *n*-3 fatty acids on the disease analysed (dyslipidemias, metabolic syndrome, obesity, cancer or cardiovascular diseases). These results suggest that the effect of *n*-3 fatty acids on the various intermediate

**Table 3.** Intervention studies analyzing *n*-3 fatty acids and genetic variants in determining intermediate and disease phenotypes

Reference	Study population	Phenotype	Genetic variant	Interaction	Main results
Lindman <i>et al.</i> <sup>(49)</sup>	Intervention study in 219 subjects from the Diet and Omega-3 Intervention Trial on atherosclerosis (DOIT). Four groups: placebo capsules, placebo and dietary advice, very long chain (VLC) <i>n</i> -3 capsules, or VLC <i>n</i> -3 capsules and dietary advice combined.	Plasma coagulation factor VII (FVII), choline-containing phospholipids and triglycerides	<i>FVII</i> gene (R353Q polymorphism)	No	The observed effects of the intervention were independent of the R353Q genotype
Lindi <i>et al.</i> <sup>(50)</sup>	Intervention study in 76 men and 74 women in a controlled trial. Subjects were randomly assigned to consume either fish oil supplements (omega-3 fatty acids/d) or placebo capsules for 3 months.	Plasma lipids and lipoproteins	<i>PPARG2</i> gene (Pro12Ala polymorphism)	Yes <i>PPARG2</i> polymorphism and <i>n</i> -3 fatty acids	The Pro12Ala polymorphism in the <i>PPARG2</i> gene may modify the inter-individual variability in plasma triglyceride response to omega-3 fatty acid supplementation. Carriers of the Ala12 allele presented a higher decrease in plasma triglycerides.
Madden <i>et al.</i> <sup>(51)</sup>	Intervention study with fish oil supplementation in patients with claudication secondary to peripheral arterial disease. Fish oil supplementation for 12 weeks.	Inflammatory markers and ankle brachial pressure index	<i>TNFA</i> , <i>IL1B</i> and <i>IL-10</i> genes	No	Any of the genotypes examined affected the results
Nelson <i>et al.</i> <sup>(52)</sup>	Intervention using alpha-linolenic acid (ALA) in healthy adult males and females. The control subjects (27) were instructed not to alter their habitual diet and the ALA group (n = 30) was instructed to follow an enriched ALA diet by using flaxseed oil capsules.	Adiponectin and lipids	<i>ADIPOQ</i> gene (276 and 45 polymorphisms)	No	The effects of ALA on adiponectin were independent of the genotype
Madden <i>et al.</i> <sup>(53)</sup>	Intervention study in 111 healthy Caucasian men. Subjects consumed habitual diets while taking 6 g MaxEPA daily for 12 weeks	Plasma lipids	<i>CD36</i> gene (polymorphisms: 25444G > A, 27645del > ins, 30294G > C, -31118G > A and -33137A > G)	Yes <i>CD36</i> (25444G > A) and EPA	The <i>CD36</i> polymorphisms modulated the effect of EPA on decreasing triglycerides and increasing HDL-C
Ferguson <i>et al.</i> <sup>(54)</sup>	LIPGENE dietary intervention cohort. 450 individuals with metabolic syndrome and dietary fat modification for 12 weeks	Biomarkers of cardiovascular risk and plasma fatty acid composition	<i>NOS3</i> gene (polymorphisms: rs11771443, rs1800783, rs1800779, rs1799983, rs3918227, and rs743507)	Yes <i>NOS3</i> rs1799983 SNP and plasma <i>n</i> -3 PUFA status	Minor allele carriers (AC + AA) of the rs1799983 showed an inverse association with significantly higher plasma triglyceride concentrations in those with low plasma <i>n</i> -3 PUFA status but the major allele homozygotes (CC) did not.

PPARG2: Peroxisome Proliferator-Activated Receptor- $\gamma$ 2; TNFA: tumor necrosis factor- $\alpha$ ; ADIPOQ: Adiponectin; IL: Interleukin; CD36: Cluster of Differentiation 36; NOS3: nitric oxide synthase 3

and disease phenotypes is highly variable and depending on genetic factors. For each phenotype studied there is a great number of genetic variants that have been shown to have significant interactions. However, these studies were at first mostly designed to show gene-diet interactions, i.e. that the phenotypical effect foreseen for a certain genetic variant could be modulated by diet, specifically by PUFA intake. Although the result of the statistical interaction is the same, the methodological approach in the study design, in data gathering, in bias control and in the specific analysis of data is different if studies are planned as diet-gene interactions, i.e. how the expected results faced with a certain amount of nutrient consumed or dietary intervention undertaken is modulated by the genetic variants.

The difference between calling a study a gene-diet interaction study as opposed to a diet-gene interaction study is as follows: The first interaction studies between genetic variants and diet were undertaken in studies that had been designed to evaluate the effect of certain genetic variants on disease phenotypes. When dietary data were provided in those studies, gene-diet interactions were also investigated. This, however, could lead to a greater bias because diet is not measured specifically from the outset of the study with the best tools for guaranteeing maximum measurement validity, but using previously obtained data. In contrast, a diet-gene interaction study is a study which, from the outset, has the aim of studying possible modulations of diet due to genetic variants, setting off from a much more valid and accurate dietary measurement. Hence, new studies are required which set off from this diet-gene interaction instead of the traditional gene-diet interaction in order to obtain better quality results. It has also been noted that there is a very low level of results replication for gene-diet interactions. Most reports are unique, in the sense that no further studies confirm or refute the findings. Publication bias may contribute to this scenario, given the fact that if later studies do not find statistically significant results, there is a high probability of not being published. Most often, journals give little priority to articles that do not contain novel results, preferring to publish new results in which new gene variants are involved even though they will never be replicated.

Furthermore, most findings are based on observational studies, whereas large-scale, carefully designed, intervention studies analysing omega3-gene interactions are absent from the literature. The drop in cost and time required to do genetic analyses combined with improved statistical and computer power, should allow new interaction studies to undertake more robust experimental approaches including multiple gene variants thus providing complete view of these interactions.

In summary, based on the available evidence, titration of *n*-3 fatty acid intake based on genetic information with the purpose of preventing or treating disease is not warranted at this time. New intervention studies, designed specifically for that purpose will be required.

### Acknowledgements

Authors Contributions: D. C. and J. M. O designed, conducted the review and analyzed and interpreted data; D. C. and

J. M. O. wrote the paper and had primary responsibility for final content. All authors read and approved the final manuscript. Funding/Support: This work was supported by grants from the Ministerio de Ciencia e Innovación and Fondo Europeo de Desarrollo Regional (FEDER): CIBER CB06/03/0035, PI07-0954, CNIC-06 and AGL2010-22319-C03-03, the Generalitat Valenciana (GVACOMP2011-151, AP111/10 and BEST11-263) and the National Heart, Lung, and Blood Institute grant HL-54776, National Institute of Diabetes and Digestive and Kidney Diseases, Grant Number DK075030. Conflicts of interest: None.

### References

1. Ordovas JM, Corella D, Cupples LA, *et al.* (2002) Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. *Am J Clin Nutr* **75**, 38–46.
2. Luan J, Browne PO, Harding AH, *et al.* (2001) Evidence for gene-nutrient interaction at the PPARGgamma locus. *Diabetes* **50**, 686–689.
3. Tai ES, Corella D, Deurenberg-Yap M, *et al.* (2004) Differential effects of the C1431T and Pro12Ala PPARGgamma gene variants on plasma lipids and diabetes risk in an Asian population. *J Lipid Res* **45**, 674–685.
4. Sampath H & Ntambi JM (2004) Polyunsaturated fatty acid regulation of gene expression. *Nutr Rev* **62**, 333–339.
5. Øverby NC, Serra-Majem L & Andersen LF (2009) Dietary assessment methods on *n*-3 fatty acid intake: a systematic review. *Br J Nutr* **102**, Suppl. 1, S56–S63.
6. Merino DM, Ma DW & Mutch DM (2010) Genetic variation in lipid desaturases and its impact on the development of human disease. *Lipids Health Dis* **9**, 63.
7. Simopoulos AP (2010) Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. *Exp Biol Med (Maywood)* **235**, 785–795.
8. Schaeffer L, Gohlke H, Müller M, *et al.* (2006) Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet* **15**, 1745–1756.
9. Malerba G, Schaeffer L, Xumerle L, *et al.* (2008) SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. *Lipids* **43**, 289–299.
10. Xie L & Innis SM (2009) Association of fatty acid desaturase gene polymorphisms with blood lipid essential fatty acids and perinatal depression among Canadian women: a pilot study. *J Nutrigenet Nutrigenomics* **2**, 243–250.
11. Xie L & Innis SM (2008) Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (*n*-6) and (*n*-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. *J Nutr* **138**, 2222–2228.
12. Lattka E, Illig T, Heinrich J & Koletzko B (2009) FADS gene cluster polymorphisms: important modulators of fatty acid levels and their impact on atopic diseases. *J Nutrigenet Nutrigenomics* **2**, 119–128.
13. Moltó-Puigmartí C, Plat J & Mensink RP (2010) FADS1 FADS2 gene variants modify the association between fish intake and the docosahexaenoic acid proportions in human milk. *Am J Clin Nutr* **91**, 1368–1376.

14. Mathias RA, Vergara C, Gao L, *et al.* (2010) FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. *J Lipid Res* **51**, 2766–2774.
15. Koletzko B, Lattka E, Zeilinger S, Illig T, *et al.* (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. *Am J Clin Nutr* **93**, 211–219.
16. Lattka E, Rzehak P, Szabó É, *et al.* (2011) Genetic variants in the FADS gene cluster are associated with arachidonic acid concentrations of human breast milk at 1.5 and 6 mo postpartum and influence the course of milk dodecanoic, tetra-cosenoic, and trans-9-octadecenoic acid concentrations over the duration of lactation. *Am J Clin Nutr* **93**, 382–391.
17. Kwak JH, Paik JK, Kim OY, *et al.* (2011) FADS gene polymorphisms in Koreans: association with  $\omega 6$  polyunsaturated fatty acids in serum phospholipids, lipid peroxides, and coronary artery disease. *Atherosclerosis* **214**, 94–100.
18. Rzehak P, Thijs C, Standl M, *et al.* (2010) Variants of the FADS1 FADS2 gene cluster, blood levels of polyunsaturated fatty acids and eczema in children within the first 2 years of life. *PLoS One* **5**, 10, e13261.
19. Lattka E, Illig T, Heinrich J, Do FADS, *et al.* (2010) genotypes enhance our knowledge about fatty acid related phenotypes? *Clin Nutr* **29**, 277–287.
20. Tanaka T, Shen J, Abecasis GR, *et al.* (2009) Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genet* **5**, 1, e1000338.
21. Aulchenko YS, Ripatti S, Lindqvist I, *et al.* (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet* **41**, 47–55 (Epub July 2008).
22. Kathiresan S, Willer CJ, Peloso GM, *et al.* (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* **41**, 56–65.
23. Tai ES, Corella D, Demissie S, *et al.* (2005) Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. *J Nutr* **135**, 397–403.
24. Chan E, Tan CS, Deurenberg-Yap M, *et al.* (2006) The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. *Atherosclerosis* **187**, 309–315.
25. Volcik KA, Nettleton JA, Ballantyne CM, *et al.* (2008) Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with *n*-6 and long-chain *n*-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. *Am J Clin Nutr* **87**, 1926–1931.
26. Lai CQ, Corella D, Demissie S, *et al.* (2006) Dietary intake of *n*-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. *Circulation* **113**, 2062–2070.
27. Verduci E, Scaglioni S, Agostoni C, *et al.* (2009) The relationship of insulin resistance with SNP 276G > T at adiponectin gene and plasma long-chain polyunsaturated fatty acids in obese children. *Pediatr Res* **66**, 346–349.
28. Ylönen SK, Salminen I, Lyssenko V, *et al.* (2008) The Pro12Ala polymorphism of the PPAR-gamma2 gene affects associations of fish intake and marine *n*-3 fatty acids with glucose metabolism. *Eur J Clin Nutr* **62**, 1432–1439.
29. Lu Y, Feskens EJ, Dollé ME, *et al.* (2010) Dietary *n*-3 and *n*-6 polyunsaturated fatty acid intake interacts with FADS1 genetic variation to affect total and HDL-cholesterol concentrations in the Doetinchem Cohort Study. *Am J Clin Nutr* **92**, 258–265.
30. Kim B, Jang Y, Paik JK, *et al.* (2010) Adiponectin gene polymorphisms are associated with long-chain  $\omega 3$ -polyunsaturated fatty acids in serum phospholipids in nondiabetic Koreans. *J Clin Endocrinol Metab* **95**, E347–E351.
31. Zhou Q, Zhang B, Wang P, Mei F, Chen CG, Sun LN, Xu Y & Su YX (2010) Association of interleukin-6 gene -572 C>G polymorphism with dietary intake of *n*-3 fatty acids on plasma HDL-c level in Chinese male adults. *Asia Pac J Clin Nutr* **19**(4), 21147711.
32. Enzenbach C, Kröger J, Zietemann V, *et al.* (2011) Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein and adiponectin in middle-aged German women and men. *Eur J Nutr*; (in press).
33. Huang T, Tucker KL, Lee YC, *et al.* (2011) Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puertorican adults. *J Nutr* **141**, 654–659.
34. Richardson K, Louie-Gao Q, Arnett DK, *et al.* (2011) The PLIN4 Variant rs8887 Modulates Obesity Related Phenotypes in Humans through Creation of a Novel miR-522 Seed Site. *PLoS One* **6**, e17944.
35. Paradis AM, Fontaine-Bisson B, Bossé Y, *et al.* (2005) The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. *Am J Clin Nutr* **81**, 523–530.
36. Rudkowska I, Garenc C, Couture P, *et al.* (2009) Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. *Genes Nutr* **4**, 199–205.
37. Rudkowska I, Caron-Dorval D, Verreault M, *et al.* (2010) PPARalpha L162V polymorphism alters the potential of *n*-3 fatty acids to increase lipoprotein lipase activity. *Mol Nutr Food Res* **54**, 543–550.
38. Gago-Dominguez M, Castelao JE, Sun CL, *et al.* (2004) Marine *n*-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore. *Carcinogenesis* **25**, 2143–2147.
39. Hedelin M, Chang ET, Wiklund F, *et al.* (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. *Int J Cancer* **120**, 398–405.
40. Fradet V, Cheng I, Casey G, *et al.* (2009) Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. *Clin Cancer Res* **15**, 2559–2566.
41. Stern MC, Siegmund KD, Corral R, *et al.* (2005) XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. *Cancer Epidemiol Biomarkers Prev* **14**, 609–615.
42. Stern MC, Butler LM, Corral R, *et al.* (2009) Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study. *J Nutrigenet Nutrigenomics* **2**, 273–279.
43. Guerreiro CS, Ferreira P, Tavares L, *et al.* (2009) Fatty acids, IL6, and TNFalpha polymorphisms: an example of

- nutrigenetics in Crohn's disease. *Am J Gastroenterol* **104**, 2241–2249.
44. Martinelli N, Girelli D, Malerba G, *et al.* (2008) FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. *Am J Clin Nutr* **88**, 941–949.
  45. Dwyer JH, Allayee H, Dwyer KM, *et al.* (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. *N Engl J Med* **350**, 29–37.
  46. Phillips CM, Goumidi L, Bertrais S, *et al.* (2009) Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. *Am J Clin Nutr* **90**, 1665–1673.
  47. Phillips CM, Goumidi L, Bertrais S, *et al.* (2010) Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. *J Nutr* **140**, 238–244.
  48. Di Pietro G, Magno LA & Rios-Santos F (2010) Glutathione S-transferases: an overview in cancer research. *Expert Opin Drug Metab Toxicol* **6**, 153–170.
  49. Lindman AS, Pedersen JI, Hjerkin EM, *et al.* (2004) The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. *Thromb Haemost* **91**, 1097–1104.
  50. Lindi V, Schwab U, Louheranta A, *et al.* (2003) Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to *n*-3 fatty acid supplementation. *Mol Genet Metab* **79**, 52–60.
  51. Madden J, Brunner A, Dastur ND, *et al.* (2007) Fish oil induced increase in walking distance, but not ankle brachial pressure index, in peripheral arterial disease is dependent on both body mass index and inflammatory genotype. *Prostaglandins Leukot Essent Fatty Acids* **76**, 331–340.
  52. Nelson TL, Stevens JR & Hickey MS (2007) Adiponectin levels are reduced, independent of polymorphisms in the adiponectin gene, after supplementation with alpha-linolenic acid among healthy adults. *Metabolism* **56**, 1209–1215.
  53. Madden J, Carrero JJ, Brunner A, *et al.* (2008) Polymorphisms in the CD36 gene modulate the ability of fish oil supplements to lower fasting plasma triacyl glycerol and raise HDL cholesterol concentrations in healthy middle-aged men. *Prostaglandins Leukot Essent Fatty Acids* **78**, 327–335.
  54. Ferguson LR, Shelling AN, Browning BL, *et al.* (2007) Genes, diet and inflammatory bowel disease. *Mutat Res* **622**, 70–83.